Skip To Main Content

Investors & Media

Company Overview
View All

LyGenesis’s cell therapies are engrafted using endoscopic ultrasound procedure, which is associated with decreased medical risks and costs relative to full organ transplantation. Our pipeline of therapies target a variety of unmet needs, including end stage liver disease, Type 1 diabetes, end stage renal disease, aging, and autoimmune disorder.

Insights Corner

Advancing Novel Therapeutic Interventions For Unmet Medical Needs

Progress, Potential And Possibilities Podcast Nov 15, 2022

Dr. Michael Hufford, Ph.D. is the Co-Founder and the Chief Executive Officer of LyGenesis, a clinical-stage cell therapy company that transforms patient’s lymph nodes into bioreactors capable of growing functioning ectopic organs.